ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Partner program
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,937 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryBaarCancer Research and Biotechnology AG
Cancer Research and Biotechnology AG Logo
Verified· 2 sourcesTrust Score
Summary

About the company

The core activity of Cancer Research and Biotechnology AG is the development of oncological drugs to combat aggressive types of cancer with high unmet medical needs. The company aims to improve the patient journey through an accelerated clinical regulatory pathway and reduce the burden of conventional treatments.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
✓ Offered3
Oncological drug development
Development of safe and effective cancer medicines for aggressive tumours, from discovery and target validation through preclinical development to IND and clinical phases.
Preclinical oncology development
Preclinical studies on drug candidates for metastatic melanoma, triple-negative breast cancer and colorectal cancer, including efficacy and safety testing.
Regulatory development and clinical translation
Accelerated pathway to first in-human, inklusive US Regulatory Affairs, Regulatory Affairs, Regulatory Advisor sowie klinischer und medizinischer Beiträge.
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.1/5

Cancer Research and Biotechnology AG

Trust & reputation

ranQ Trust Score of Cancer Research and Biotechnology AG: 4.1 out of 5.0

Trust Score4.1/ 5.0

High

x

Data basis 54% · As of October 2026

Without public customer reviews the score stays capped.

Cancer Research and Biotechnology AG has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
Cancer Research and Biotechnology AG scores 82.0 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.83.012%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.70.07%
Cancer Research and Biotechnology AG scores 83.3 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).83.322%
Cancer Research and Biotechnology AG scores 6.9 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.6.94%
  • Media authority: No data point — the criterion is taken out of the weighting and does not lower the score.—4%
Qualifications+0.00

Cancer Research and Biotechnology AG reaches a ranQ Trust Score of 4.1 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 54%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Knowledge

No knowledge articles yet

Once Cancer Research and Biotechnology AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Cancer Research and Biotechnology AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Cancer Research and Biotechnology AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Cancer Research and Biotechnology AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Obere Rebhalde 32
6340 Baar

At a glance

Legal form
Corporation
UID
CHE-428.033.043
Founded
2017 · 9 years
Last commercial register change
October 8, 2026
Employees
11 to 20
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.100.06%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    CL
    Centenara Labs AG
    Baar
    OG
    OrchestratePharma GmbH
    Baar
    VH
    ViiV Healthcare GmbH
    Baar
    NT
    Nektar Therapeutics Europe GmbH
    Zug
    OA
    Oncoteq AG
    Cham
    EA
    Elthera AG
    Zug
    C(
    Cytokinetics (Switzerland) GmbH
    Zug
    CA
    Cellis AG
    Zug